Nearly everyone is anxious… There’s talk of a global recession, much of the U.S. government remains closed for business, China’s economy is looking wobbly, and then there’s the ongoing trade war with that country. Not to mention slowing sales growth from notable companies like Apple (Nasdaq: AAPL) and American Airlines (Nasdaq: AAL). And disappointing holiday sales that have crushed the share prices of many retailers, notably Macy’s (NYSE: M), which is down about 24% since January 9. The latest wall of worry for the market and the economy is that this earnings season is expected to be slower than previous… Read More

Nearly everyone is anxious… There’s talk of a global recession, much of the U.S. government remains closed for business, China’s economy is looking wobbly, and then there’s the ongoing trade war with that country. Not to mention slowing sales growth from notable companies like Apple (Nasdaq: AAPL) and American Airlines (Nasdaq: AAL). And disappointing holiday sales that have crushed the share prices of many retailers, notably Macy’s (NYSE: M), which is down about 24% since January 9. The latest wall of worry for the market and the economy is that this earnings season is expected to be slower than previous quarters. Now, keep in mind that the last three quarters have seen earnings growth of more than 24%. That’s a high standard to beat. To give you an idea of what sort of bar has been set, just look at last quarter’s performance. In the third quarter of 2018, corporate earnings grew by a massive 25.9% over the year-earlier quarter, the strongest such growth in eight years. But expectations for fourth-quarter earnings are much less lofty, as analysts steadily drop their estimates. As recently as September, analysts expected earnings to grow by 17%, but that number has been knocked down… Read More

One of my favorite colloquialisms is “50% of something is better than 100% of nothing.” It’s best when said with a grizzled Southern accent with a big dip of Copenhagen wedged in the speaker’s lip. —Recommended Link— Ex-Military Intelligence Officer Finally Reveals He Secret To Her 90.9% Success Rate Today only save 62% on the system that is helping smart investors like you make massive gains…hurry, wall street insiders hope to shut this down soon… Click here before it’s too late. Kidding aside, this phrase is one of the many mantras… Read More

One of my favorite colloquialisms is “50% of something is better than 100% of nothing.” It’s best when said with a grizzled Southern accent with a big dip of Copenhagen wedged in the speaker’s lip. —Recommended Link— Ex-Military Intelligence Officer Finally Reveals He Secret To Her 90.9% Success Rate Today only save 62% on the system that is helping smart investors like you make massive gains…hurry, wall street insiders hope to shut this down soon… Click here before it’s too late. Kidding aside, this phrase is one of the many mantras grown-up investors will use from time to time. Markets and stocks will and do go down at some point. It’s one of the few guarantees that come with the territory. We all want to do well on the upside. But with an unavoidable downside, the key is to do less worse than the market. It’s doable. #-ad_banner-#The fancy term money managers throw around is “downside capture.” As ridiculous as it sounds, it’s a thing. And it works. There’s an actual portfolio called the downside capture ratio. However, rather than getting too far into those weeds, the ultimate goal of downside… Read More

When Thomas Edison died, or Einstein, or Dr. Feynman, for that matter… we knew what we had lost. The scientific community grieved. But when a scientist whose discovery might prove to be in any one or even all of their leagues died on Feb. 18 of last year, it felt as though the news went almost unnoticed. Gunter Blobel was a molecular biologist. In 1999, he was awarded the Nobel Prize in medicine. He had determined that proteins in any living cell have a sort of ZIP code system that guides them to where they need to go to take… Read More

When Thomas Edison died, or Einstein, or Dr. Feynman, for that matter… we knew what we had lost. The scientific community grieved. But when a scientist whose discovery might prove to be in any one or even all of their leagues died on Feb. 18 of last year, it felt as though the news went almost unnoticed. Gunter Blobel was a molecular biologist. In 1999, he was awarded the Nobel Prize in medicine. He had determined that proteins in any living cell have a sort of ZIP code system that guides them to where they need to go to take care of tissue, organs, and biochemistry. Blobel’s mentor at Rockefeller University, Dr. George Palade, was a wizard with electron microscopes — his work earned him the Nobel in 1974. Blobel figured out that there are about a quadrillion cells in the human body, each containing about a billion protein molecules that are spun out of little cavities known as endoplasmic reticula. These proteins are all guarded by special membranes. He and a colleague hypothesized that each of these proteins also contains proteins that act as airport luggage tags, as his obituary in the Times put it. It turns out this… Read More

Recent market volatility has forced investors to seek safer investments for their portfolios. For many, stocks with a solid dividend-paying history with a low beta (β) offer a safer alternative to other stocks. —Recommended Link— Save 75% On Fast-Track Millionaire Today Tired of just barely beating the market? See how we’re crushing the market hand over fist inside Fast-Track Millionaire. Details here. For those unfamiliar with beta, β measures the volatility of a stock against a broad market index, such as the S&P 500. Because the market is given a beta of 1, anything with less volatility than the… Read More

Recent market volatility has forced investors to seek safer investments for their portfolios. For many, stocks with a solid dividend-paying history with a low beta (β) offer a safer alternative to other stocks. —Recommended Link— Save 75% On Fast-Track Millionaire Today Tired of just barely beating the market? See how we’re crushing the market hand over fist inside Fast-Track Millionaire. Details here. For those unfamiliar with beta, β measures the volatility of a stock against a broad market index, such as the S&P 500. Because the market is given a beta of 1, anything with less volatility than the market will have a beta below 1. Conversely, if a stock has greater volatility than the market as a whole, that stock will have a beta greater than 1. Given the wild ride investors have experienced since October, finding solid dividend stocks with low betas is imperative. Should the market volatility continue unabated, huge drawdowns are possible with high beta stocks. Fortunately, finding such stocks isn’t too difficult. One such stock is ExxonMobil (NASDAQ: XOM). As you can see from the chart below, the stock suffered in 2018 — losing 18.6%. While the stock is off its recent… Read More

For biotech investors, the year has started with a bang. First, it was Bristol-Myers Squibb’s (NYSE: BMY) enormous $74 billion bid for Celgene (Nasdaq: CELG), one of the largest biotech companies in the world. Right on its heels came a smaller but still significant move — the announcement on Jan. 7 of Eli Lilly’s (NYSE: LLY) intended $8 billion acquisition of Loxo Oncology (Nasdaq: LOXO). —Recommended Link— Market Rally Forecast For The Next 3 Days Did you know the stock market rallied during every government shutdown over the past 25 years? In fact, this time,… Read More

For biotech investors, the year has started with a bang. First, it was Bristol-Myers Squibb’s (NYSE: BMY) enormous $74 billion bid for Celgene (Nasdaq: CELG), one of the largest biotech companies in the world. Right on its heels came a smaller but still significant move — the announcement on Jan. 7 of Eli Lilly’s (NYSE: LLY) intended $8 billion acquisition of Loxo Oncology (Nasdaq: LOXO). —Recommended Link— Market Rally Forecast For The Next 3 Days Did you know the stock market rallied during every government shutdown over the past 25 years? In fact, this time, it’s already up 10%… and still going. There’s a trade that exploits this situation exceptionally well, and you can take advantage of it over the next 3 days. You can find the full details here. I think we can expect even more deals as the year progresses. And that, of course, is potentially great news for investors… There are several industry-specific factors making it imperative that the flow of deals continues. For several years now, large pharma has been facing a crisis of sorts. The business model of drug companies has long been based on having… Read More

This may be the year we see retail roar back. If you remove the last quarter of 2018, the sector posted strong performance numbers. Surging behind low unemployment, climbing consumer confidence, and a better-than-expected holiday season, retail hit fresh highs in 2018. Then, along with the rest of the market, the bottom fell out in December with stocks plunging to their worse end-of-year performance since the Great Depression. —Recommended Link— Wall Street Won’t Tell You About This… But We Just Uncovered A Bombshell… I’ve created an in-depth report for this opportunity and it covers what I believe is the… Read More

This may be the year we see retail roar back. If you remove the last quarter of 2018, the sector posted strong performance numbers. Surging behind low unemployment, climbing consumer confidence, and a better-than-expected holiday season, retail hit fresh highs in 2018. Then, along with the rest of the market, the bottom fell out in December with stocks plunging to their worse end-of-year performance since the Great Depression. —Recommended Link— Wall Street Won’t Tell You About This… But We Just Uncovered A Bombshell… I’ve created an in-depth report for this opportunity and it covers what I believe is the biggest investment opportunity we’ll see in our lifetime… It will change the concept of what it means to be human, as we see major diseases eradicated… and as our life expectancy reaches 120 years. I’ve been tracking this development for seven years… At the same time, consumer confidence remains high, oil prices low, and employment solid in the face of the retail rout. Add in the abating Chinese tariff pressures and a bullish picture is painted for retail and the overall market in 2019. #-ad_banner-#Strategically buying dips is a time-honored way to profit from the stock market. December beat retail… Read More

The next week will be an interesting week in the stock market. Of course, there’s never any shortage of events that could change the outlook for the market one way or another… But according to a chart of the S&P 500, it looks like we’re at an important technical resistance level. Resistance is an important technical term for a price level where a security’s advance is expected to stall. In other words, it’s a price level where sellers appear, and their actions can often be anticipated. In the chart below, I’ve labeled three factors that are all pointing toward resistance… Read More

The next week will be an interesting week in the stock market. Of course, there’s never any shortage of events that could change the outlook for the market one way or another… But according to a chart of the S&P 500, it looks like we’re at an important technical resistance level. Resistance is an important technical term for a price level where a security’s advance is expected to stall. In other words, it’s a price level where sellers appear, and their actions can often be anticipated. In the chart below, I’ve labeled three factors that are all pointing toward resistance near the S&P 500’s current level around 2,600… 1. The March lows (blue dashed line): Many investors like to buy stocks when they approach previous lows, as it often represents a “safe” bargain price. We saw this in action back in October and November, when stocks fell to their March lows (which then represented “support”) and were met with aggressive buying. However, stocks suffered a rapid loss in December, so anyone who bought at last year’s lows is just getting back to even. From what I’ve observed, many traders tend to sell the moment their positions get back… Read More

Money and health… As the calendar flips over to a new year, these two areas of our lives tend to become a focal point for improvement. On the money side of things, we assess our financial house and set goals (read resolutions) to pay down debt, save more, increase income, and reevaluate our retirement strategy. —Recommended Link— How To Play The Government Shutdown For Maximum Portfolio Gain Since the government has shut its doors, the market has already soared 10%. Here’s the best trade to profit from it over the next week. Read More

Money and health… As the calendar flips over to a new year, these two areas of our lives tend to become a focal point for improvement. On the money side of things, we assess our financial house and set goals (read resolutions) to pay down debt, save more, increase income, and reevaluate our retirement strategy. —Recommended Link— How To Play The Government Shutdown For Maximum Portfolio Gain Since the government has shut its doors, the market has already soared 10%. Here’s the best trade to profit from it over the next week. Click here. On the health side of the equation, we want to lose weight, eat healthier, and build muscle. Gym memberships typically skyrocket this time of year, diet books are sold out, and health-monitoring devices fly off the shelves.  It’s no surprise that these are the two areas that receive the most attention. After all, household debt totaled $13.5 trillion at the end of last year’s third quarter — an all-time high. When looking only at credit card debt, student, auto, and personal loans, that figure stood at nearly $4 trillion, surpassing the previous high-water mark set in the… Read More

After finishing 2018 as one of the worst-performing sectors, it looks like biotech could be a runaway leader this year. The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) has surged 13% so far this year, nearly four-fold the return on the S&P 500, after having crashed 11.8% last year. Valuation multiples are down and acquisition activity for 2019 is already 26% of last year’s total. —Recommended Link— How To Make Massive Gains When The Market Tumbles Industry veteran invites 50 investors to join him in the world’s only legal market hack that actually works… discover how to bring home an… Read More

After finishing 2018 as one of the worst-performing sectors, it looks like biotech could be a runaway leader this year. The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) has surged 13% so far this year, nearly four-fold the return on the S&P 500, after having crashed 11.8% last year. Valuation multiples are down and acquisition activity for 2019 is already 26% of last year’s total. —Recommended Link— How To Make Massive Gains When The Market Tumbles Industry veteran invites 50 investors to join him in the world’s only legal market hack that actually works… discover how to bring home an extra $37,000 in the next 365 days or less. Biotech is one of the few industries that should remain relatively immune from worries over the trade war and could be a bright spot in an otherwise volatile year. #-ad_banner-#In perhaps no other industry is stock-picking more important than in biotech. Investor sentiment could boost the entire group, but it will be the individual companies with breakthrough drugs that will provide outsized returns. Get Ready For The 2019 Biotech Boom The market was largely disappointed in biotech acquisitions last year and investors reflected their dissatisfaction in share prices. Passage of… Read More